Skip to content

Effectiveness of Nefopam in Breast Cancer Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02949310
Enrollment
88
Registered
2016-10-31
Start date
2016-10-31
Completion date
2018-12-31
Last updated
2018-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm Malignant Primary

Brief summary

Breast cancer surgery is known to cause severe acute postoperative pain, which can persist for a long time. The investigators administered nefopam preventively to patients undergoing total mastectomy or modified radical mastectomy with axillary lymph node dissection or sentinel lymph node biopsy, and evaluated its efficacy on acute and chronic postoperative pain.

Interventions

DRUGNefopam
DRUGNormal Saline

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Total mastectomy * Modified radical mastectomy * Nipple-sparing mastectomy * American Society of Anesthesiologists physical status I or II * Postoperative use of intravenous patient-controlled analgesia

Exclusion criteria

* Chronic analgesia medication * Pregnancy * Lactating women * Previous operation history due to breast cancer * Cooperation with other surgery * Contraindication of nefopam

Design outcomes

Primary

MeasureTime frame
Change of cumulative analgesia volume infused via intravenous patient-controlled analgesia deviceAt postoperative 4 hour, 24 hour, 48 hour, 72 hour, 10 day, and 3 month

Secondary

MeasureTime frame
Change of numerical rating scale for postoperative painAt postoperative 4 hour, 24 hour, 48 hour, 72 hour, 10 day, and 3 month

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026